Furthermore, clinical and experimental studies show that the efficacy of the three currently licensed anti-TNF agents (infliximab, etanercept and adalimumab) may vary and depend on the type of ...
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...
Tharimmune (THAR) announced preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized ...
Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. Objective: To investigate the use of a biologic TNF-alpha inhibitor, etanercept was ...
Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...
TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or ...
A study by Strangfeld et al. adds specificity by showing a moderately increased risk of herpes zoster in patients receiving anti-TNF antibody treatment, and raises the question of whether live ...
In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha (TNF-α) inhibitor, in serum with concentrations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback